Clinical Trials on Carcinoma, Melanoma in Hong Kong

Total 657 results

Takeda

Completed

A Chart Review Study of Adults With Advanced NSCLC (EXTRACT)

Non-small Cell Lung Cancer (NSCLC)

Hong Kong, France, Canada
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
BeiGene

Active, not recruiting

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent or Metastatic Nasopharyngeal Cancer

China, Taiwan, Thailand
Bristol-Myers Squibb

Completed

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction

France, Poland, Russian Federation, Taiwan, United States, Hong Kong, Spain, Germany, Italy, Japan, Korea, Republic of, Singapore
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
Hoffmann-La Roche

Completed

A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Carcinoma, Hepatocellular

United States, Belgium, Korea, Republic of, Hong Kong, United Kingdom, Japan, Italy, Spain, Singapore, Taiwan, Germany, France, New Zealand
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Advanced Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States, Canada, Australia, Hong Kong, Korea, Republic of
Amgen

Recruiting

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Melanoma

Italy, Spain, Czechia, Serbia, Estonia, Bosnia and Herzegovina, Portugal, Romania, Georgia, Lithuania, Malaysia, United States, Taiwan, France, Canada, Chile, Thailand, Croatia, Germany, Mexico, Philippines, Turkey
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Aventis Pharmaceuticals

Terminated

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Shanghai Henlius Biotech

Recruiting

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Limited-Stage Small Cell Lung Cancer

United States, China, Greece, Spain, Austria, Czechia, Germany, Hungary, Latvia, Netherlands, Poland
Bristol-Myers Squibb

Completed

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Melanoma | Metastases

United States, Canada, Netherlands, United Kingdom, Germany, Chile, Belgium, France, South Africa, Argentina, Brazil, Hungary, Switzerland
Amgen

Recruiting

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Small Cell Lung Carcinoma

United States, Spain, Austria, Switzerland, United Kingdom, France, Australia, Germany, Japan, Taiwan, Poland, Hong Kong, Netherlands
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Neoplasms | Non-squamous, Non-Small-Cell Lung Cancer

United States, Spain, Korea, Republic of, France, Hong Kong, United Kingdom, Germany, Australia, Taiwan, Poland, Russian Federation, Ukraine
Amgen

Recruiting

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Melanoma

Italy, Spain, South Africa, Japan, Serbia, Bosnia and Herzegovina, United States, Argentina, Chile, Georgia, Malaysia, Korea, Republic of, France, Germany, Croatia, Thailand, Brazil, Taiwan, Romania, Mexico, Netherlands
Pharmacyclics LLC.

Terminated

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States
Bayer

Completed

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib (GIDEON)

Carcinoma, Hepatocellular

Japan, China, Slovakia, Croatia, France, Hungary, Indonesia, Korea, Republic of, Malaysia, Singapore, Spain, Sweden, Thailand, Philippines, Colombia, Czech Republic, Hong Kong, Italy, Kazakhstan, Mexico, Romania, Russian Federation, Ukrain... and more
Janssen Research & Development, LLC

Terminated

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China
AstraZeneca

Completed

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (AURA2)

Non Small Cell Lung Cancer

Italy, United States, Canada, Korea, Republic of, Japan, Taiwan, Hong Kong, Spain
Translational Research in Oncology
Bayer

Recruiting

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 (REPLACE)

Carcinoma, Hepatocellular

Korea, Republic of, United States, Taiwan, Spain, Japan, France, Georgia, Belgium, Germany, Turkey, Italy, Hong Kong, Serbia
Tularik

Terminated

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma

United States, Russian Federation, United Kingdom, Singapore, Thailand, Ukraine, Brazil, China, Poland, Puerto Rico, South Africa
Aristotle University Of Thessaloniki

Not yet recruiting

Predictive Factors for Medullary Thyroid Cancer Aggressiveness (MYELO)

Medullary Thyroid Cancer

China, Switzerland, Spain, Greece, United States, Austria, Belgium, Brazil, Bulgaria, Colombia, Croatia, France, India, Iraq, Italy, Jordan, Morocco, Poland, Serbia, Slovakia, Thailand, Turkey, Ukraine, Vietnam
Xoft, Inc.
Icad, Inc.

Active, not recruiting

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

Ductal Carcinoma in Situ | Invasive Ductal Carcinoma

United States, Portugal, Australia
Novartis Pharmaceuticals

Recruiting

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | KRAS G12C Mutant Solid Tumors | Carcinoma, Colorectal

United States, Japan, Australia, Germany, Italy, Spain, Canada, Denmark, Korea, Republic of, Taiwan, Belgium, Hong Kong, China, France, Singapore, Netherlands
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Non-Small Cell Lung Cancer

Australia, Belgium, France, Italy, Hong Kong, Canada, Denmark, Taiwan, Russian Federation, United Kingdom, Spain, Hungary, Czech Republic, Poland, Germany, Netherlands
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (CheckMate722)

Non-Small-Cell Lung Carcinoma

United States, China, Taiwan, Spain, Korea, Republic of, France, Canada, Hong Kong, Japan, Singapore
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (CheckMate040)

Hepatocellular Carcinoma

United States, Singapore, Spain, United Kingdom, Germany, Italy, Canada, France, Hong Kong, Japan, Korea, Republic of, Puerto Rico, Taiwan
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Completed

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

Stage IA Uterine Corpus Cancer AJCC v7 | Stage IB Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus... and other conditions

United States, Canada, Hong Kong
AstraZeneca

Active, not recruiting

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (PACIFIC-5)

Carcinoma, Non-Small-Cell Lung

Poland, Taiwan, India, Mexico, Russian Federation, Turkey, China, Korea, Republic of, Philippines, Hong Kong
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Hepatocellular Carcinoma | Hepatoma | Liver Cell Carcinoma | Liver Cancer, Adult | Liver Cell Carcinoma, Adult

Chile, Brazil, Argentina, China, Czechia, France, Hong Kong, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Romania, Singapore, Spain, Taiwan, Turkey
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Anemia

Belgium, Italy, Poland, Spain, Hong Kong, Canada, France, Greece, Czech Republic, Austria, Estonia, Hungary, Australia, Germany, Finland
Daping Hospital and the Research Institute of Surgery...

Unknown

Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Gilead Sciences

Active, not recruiting

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC)

Head and Neck Squamous Cell Carcinoma

United States, France, Spain, Australia, Italy, Belgium, Hong Kong, Portugal, Poland, United Kingdom, Germany
AstraZeneca

Completed

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (IPASS)

Non-Small Cell Lung Cancer

Philippines, China, Malaysia, Japan, Hong Kong, Taiwan, Thailand, Indonesia, Singapore
Imunon

Completed

Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, Taiwan, Korea, Republic of, China, Italy, Hong Kong, Thailand, Canada, Malaysia, Japan, Philippines
Bristol-Myers Squibb

Recruiting

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106)

Carcinoma, Hepatocellular

United States, Taiwan, Spain, France, Korea, Republic of, Germany, Puerto Rico, China, Japan, Canada, Hong Kong, Australia, Poland, Singapore, Italy
Pfizer

Completed

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

France, Belgium, United States, Taiwan, Hong Kong, United Kingdom, Germany, Italy, China, Hungary, Japan, Slovakia, Korea, Republic of
AVEO Pharmaceuticals, Inc.
Biodesix, Inc.

Terminated

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)

Non-small Cell Lung Cancer

Korea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Squamous Cell Carcinoma of the Head and Neck

Brazil, Italy, United Kingdom, United States, Hong Kong, France, Netherlands, Germany, Argentina, Canada, Japan, Korea, Republic of, Spain, Switzerland, Taiwan
Bayer

Completed

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, France, Switzerland, Germany, United States, Austria, New Zealand, Hungary, Korea, Republic of, Italy, Hong Kong, Thailand, Spain, Taiwan, Japan, Czechia, United Kingdom
Pfizer

Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Brazil, Spain, United Kingdom, Singapore, Canada, Hong Kong, Poland, Puerto Rico
BioAtla, Inc.

Recruiting

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Non-Small-Cell Lung Cancer

United States, Hong Kong, Taiwan, Spain, Greece, Germany, Italy, Poland
AstraZeneca

Completed

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)

Carcinoma, Non- Small Cell Lung

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Peru, Russian Federation, Hong Kong, Israel, Greece, Australia, Singapore, Turkey, India, A...
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Glioma | Cholangiocarcinoma | Chondrosarcoma | Any Solid Tumor

United States, Spain, Korea, Republic of, Australia, Japan, Taiwan, France, Singapore, Hong Kong
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
Eli Lilly and Company

Withdrawn

A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States
Novartis Pharmaceuticals

Completed

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Non-Small Cell Lung Cancer

Canada, Italy, United Kingdom, Spain, Netherlands, Singapore, Germany, Hong Kong, Japan, France, Korea, Republic of, United States
Hoffmann-La Roche

Completed

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Non-small Cell Lung Cancer

Belgium, Italy, Portugal, Spain, Germany, Turkey, France, Hong Kong, Korea, Republic of, Poland, Russian Federation, Hungary, Norway, Bulgaria, Slovakia
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States

Clinical Trials on Carcinoma, Melanoma in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations